A latest study has discovered a potential drug therapy that is believed to have positive effects in treatments for adults suffering from fragile X syndrome. This study was conducted by the Rush University Medical Center, Chicago, and the UC Davis M.I.N.D. Institute.
Fragile X syndrome is said to be the most common cause of autism. It is mostly believed to be caused by intellectual disability. It is estimated that every 1 in 3000 people may get affected with this disorder.
Study lead author, Elizabeth Berry-Kravis, pediatric neurologist at Rush, says that, “Currently there are no therapies on the market to treat cognitive deficits associated with fragile X syndrome. This pilot study has identified the potential beneficial clinical effects of fenobam, but further study is needed.”
Senior investigator, Randi Haqerman, a developmental and behavioral pediatrician and also medical director of the UC Davis M.I.N.D. Institute, says that, “All children with autism or intellectual disability should be tested for the fragile X mutation. This targeted treatment for fragile X syndrome may be helpful for a subgroup of children with autism, too.”
In an attempt to test this therapy, a study was conducted on around 12 subjects. Each subject received a single dose of fenobam.
The study results revealed a 20 percent improvement in about six of the subject’s attention span, sensory gating, and inhibition. Berry-Kravis says that the reaction of some of the study subjects to fenobam was an immediate decrease in anxiety and hyperactivity and they exhibited a calm behavior.
Their findings are published online on Journal of Medical Genetics.